KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Self-Reported Cognitive Function and Quality of Life in Patients With SCLC in the Hippocampal Avoidance Prophylactic Cranial Irradiation Versus Prophylactic Cranial Irradiation Randomized Phase 3 Trial (NCT01780675). PMID 37284297 · JTO Clin Res Rep · 2023-May The report describes a Phase 3 randomized trial in human oncology (SCLC) comparing two radiotherapy techniques (PCI vs. HA-PCI). However, the intervention is non-drug (radiation therapy), and the primary endpoints are patient-reported cognitive function and quality of life, not a time-to-event efficacy endpoint such as OS, PFS, DFS, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The randomised thoracoscopic talc poudrage+indwelling pleural catheters versus thoracoscopic talc poudrage only in malignant pleural effusion trial (TACTIC): study protocol for a randomised controlled trial. PMID 37253535 · BMJ Open Respir Res · 2023-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. PMID 37236636 · J Immunother Cancer · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact on Health-Related quality of life after wearing compression garment or not for six months in women with mild breast cancer-related arm lymphedema. A cross-sectional study. PMID 37211678 · Acta Oncol · 2023-May The record describes a randomized trial in oncology (breast cancer-related lymphedema) but the intervention is a non-drug device (compression garment) and the primary endpoint is quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). Therefore, it does not meet the eligibility criteria for a drug intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Digital solution in the follow-up of early breast cancer a randomized study. PMID 37190970 · Acta Oncol · 2023-May The record describes a randomized trial in early breast cancer comparing a digital follow-up solution to phone-based follow-up. It is oncologic, human, randomized, and reports original results. However, it is ineligible because (1) it lacks a drug-containing intervention, (2) its primary endpoint is patient preference, not a time-to-event efficacy endpoint, and (3) the trial phase is not explicitly defined as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy for spine metastases: a review of 24 Gy in 2 daily fractions. PMID 37155133 · J Neurooncol · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. PMID 37142383 · Lancet Oncol · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. PMID 37142372 · Lancet Oncol · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. PMID 37142291 · J Immunother Cancer · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The role of warm ischemia time on functional outcomes after robotic partial nephrectomy: a radionuclide renal scan study from the clock randomized trial. PMID 37085644 · World J Urol · 2023-May The study is a randomized Phase III trial in human kidney neoplasms, but it evaluates a surgical technique (on- vs off-clamp robotic partial nephrectomy) and does not involve a drug-containing intervention. The primary endpoints are functional outcomes (eGFR, split renal function), not time-to-event efficacy endpoints.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. PMID 37079223 · Target Oncol · 2023-May The record is a retrospective, non-randomized registry analysis comparing real-world outcomes to a historical trial. It does not meet the core criteria of being an original report of a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. PMID 37075617 · Lung Cancer · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome. PMID 37072559 · Clin Pharmacokinet · 2023-May The record is a modeling/simulation study that uses data from the phase III ENDEAVOR trial to compare dosing intervals. It is not an original, formal-result report of the trial's efficacy/safety outcomes. It lacks direct evidence of randomization in this specific report (though the underlying trial was randomized), and it does not present primary or key secondary efficacy results from the trial itself. It is a secondary analysis focused on PK/PD modeling.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. PMID 37069326 · Leukemia · 2023-May The report is an original result from a Phase III randomized trial with a drug intervention (asciminib vs. bosutinib) in human oncology (CML). However, it is explicitly a quality-of-life analysis, not a primary or key secondary analysis of a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort focused on time-to-event efficacy.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. PMID 37059507 · Lancet Neurol · 2023-May 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. PMID 37052120 · J Comp Eff Res · 2023-May This is a quality-of-life mapping study that uses data from a Phase III randomized trial for health-state utility estimation for cost-effectiveness analysis. It does not report on the trial's primary or key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Identifying Patterns in Preoperative Communication about High-Risk Surgical Intervention: A Secondary Analysis of a Randomized Clinical Trial. PMID 37036062 · Med Decis Making · 2023-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. PMID 37011650 · Lancet Oncol · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use. PMID 37000339 · CNS Drugs · 2023-May 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. PMID 36996624 · Eur J Cancer · 2023-May All required criteria are explicitly met except the trial phase. The metadata does not confirm Phase III/IIIb or Phase II/III status. The study is a randomized trial with a drug intervention and primary time-to-event efficacy results, but the phase is not established in the provided record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. PMID 36968576 · Clin Transl Radiat Oncol · 2023-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. PMID 36968218 · JHEP Rep · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The optimal number of examined lymph nodes for accurate nodal staging and favorable prognosis of oral tongue squamous cell carcinoma. PMID 36966671 · Oral Oncol · 2023-May The record is a retrospective database analysis of surgical staging in oral cancer, not a Phase II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Robot-Assisted Laparoscopic Radical Prostatectomy Using the KangDuo Surgical Robot System vs the da Vinci Si Robotic System. PMID 36924278 · J Endourol · 2023-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
To go or not to go in phase 2/3 oncology trials, a critical question with a unified answer. PMID 36921690 · Contemp Clin Trials · 2023-May This is a methodological article discussing trial design strategy, not an original report of a randomized controlled trial with patient outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. PMID 36921494 · Eur J Cancer · 2023-May The record describes a randomized trial with a drug intervention and a primary PFS endpoint in metastatic colorectal cancer, which is an oncology malignancy. However, the trial phase (e.g., Phase III) is not explicitly stated in the provided title, abstract, or metadata. The eligibility criterion requires explicit establishment of Phase III/IIIb or Phase II/III, which is not met here.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review. PMID 36907793 · Clin Lung Cancer · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). PMID 36905771 · Eur J Cancer · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. PMID 36897465 · Breast Cancer Res Treat · 2023-May The record describes a secondary pooled analysis of randomized data, but the primary efficacy endpoints are pathologic response rates (pCR/cCR), not time-to-event outcomes like OS or PFS. The phase of the underlying trials is also not definitively established as Phase III/IIIb or Phase II/III from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A protocol for a cluster randomized trial of care delivery models to improve the quality of smoking cessation and shared decision making for lung cancer screening. PMID 36878389 · Contemp Clin Trials · 2023-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial. PMID 36875870 · Clin Transl Radiat Oncol · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. PMID 36868932 · Eur Urol · 2023-May The record is eligible as it reports a formal result from a randomized Phase III oncology trial with a drug intervention and a time-to-event efficacy endpoint. The analysis is a pre-specified biomarker subgroup analysis within the trial's results, not a post-hoc or biomarker-only study.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. PMID 36863484 · Ann Oncol · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. PMID 36859649 · Breast Cancer Res Treat · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. PMID 36842849 · Cytotherapy · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. PMID 36813867 · Br J Cancer · 2023-May The record describes a biomarker analysis study using data from the SIEGE randomized trial. While it includes correlations with overall survival (OS), the primary purpose and focus of this specific publication is to evaluate predictive biomarkers (e.g., ctDNA, albumin) for treatment response and survival. This is a secondary, exploratory, or correlative science analysis, not the original formal report of the trial's primary or key secondary time-to-event efficacy results. Therefore, it is excluded based on the criteria for 'original formal-result reports'.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prognostic score from a multicentric retrospective analysis of patients affected by sarcoma with metachronous lung metastases undergoing metastasectomy. PMID 36807911 · J Surg Oncol · 2023-May The study is an oncology retrospective analysis of human patients with sarcoma lung metastases, reporting time-to-event efficacy endpoints (OS, DFS) with Kaplan-Meier estimates and HR. However, it is explicitly a retrospective analysis (not randomized), does not involve a drug-containing intervention (surgery only), and is not a Phase III/IIIb or Phase II/III randomized trial. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perceptions of prognosis and end-of-life care outcomes in patients with advanced lung and gastrointestinal cancer. PMID 36802979 · Palliat Med · 2023-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A double-blinded, randomized trial comparing surgeon-administered transversus abdominis plane block with placebo after midline laparotomy in gynecologic oncology surgery. PMID 36791986 · Am J Obstet Gynecol · 2023-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2023;83:103-9. PMID 36774223 · Eur Urol · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Danish Women Want to Participate in a Hypothetical Breast Cancer Screening with Harms and No Reduction in Mortality: A Cross-Sectional Survey. PMID 36734154 · Med Decis Making · 2023-May This is a cross-sectional survey study about attitudes toward hypothetical breast cancer screening, not a randomized trial of a drug intervention with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program. PMID 36715850 · Clin Rheumatol · 2023-May 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Number of positive lymph nodes combined with the logarithmic ratio of positive lymph nodes predicts long-term survival for patients with node-positive parotid gland carcinoma after surgery: a SEER population-based study. PMID 36715737 · Eur Arch Otorhinolaryngol · 2023-May The study is a population-based prognostic analysis of lymph node staging in parotid gland carcinoma using SEER data. It is not a randomized controlled trial of a drug intervention; it is a retrospective cohort analysis for nomogram development and validation. Although publication types include 'Randomized Controlled Trial', the content clearly describes a non-randomized, non-interventional, population-based prognostic study. No drug intervention is present.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice. PMID 36708469 · Am J Hematol · 2023-May The record is from a phase 3 randomized oncology trial with a drug intervention and presents original results. However, it is ineligible because it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The analysis focuses exclusively on quality of life and symptom scores.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. PMID 36700417 · Diabetes Obes Metab · 2023-May The record is a safety/tolerability analysis of semaglutide in type 2 diabetes, not a human malignant-neoplasm trial. While randomized and Phase IIIa, the primary endpoint is safety (adverse events), not a time-to-event efficacy endpoint (OS, PFS, etc.).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases. PMID 36692613 · Ann Surg Oncol · 2023-May The record describes a retrospective prognostic model study (nomogram) for predicting treatment failure after surgery for colorectal liver metastases, with a random data split for internal validation. Although it has randomized elements (data split) and reports survival outcomes, it is not a Phase III/IIIb or Phase II/III randomized controlled trial of a drug intervention. The primary endpoint is a composite for logistic regression modeling, not a time-to-event efficacy endpoint from a clinical trial. Therefore, it fails the 'phase3_or_definitive' and 'drug_intervention' criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Therapeutic landscape and future direction of metastatic colorectal cancer. PMID 36670267 · Nat Rev Gastroenterol Hepatol · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. PMID 36646209 · J Thorac Oncol · 2023-May The record describes a secondary/prognostic analysis (radiomic signature development) from randomized Phase III trials (CheckMate-017, -026, -063), but the phase is not explicitly stated in the provided metadata or abstract text. The primary focus is biomarker validation, not the original primary efficacy result of the drug intervention. Therefore, eligibility cannot be fully established without confirmation of the trial phase and whether this is the primary trial report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial. PMID 36609010 · Eur Urol · 2023-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Underwater versus conventional EMR of large nonpedunculated colorectal lesions: a multicenter randomized controlled trial. PMID 36572129 · Gastrointest Endosc · 2023-May The record describes a randomized, multicenter trial in human oncology (colorectal neoplasms), but it is ineligible because it lacks a drug intervention and a time-to-event efficacy endpoint. The study compares two endoscopic procedural techniques, and the primary outcome is a recurrence rate, not a time-to-event measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -